Back to Search
Start Over
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study
- Source :
- Antiviral therapy, 14(8), 1065-1074. International Medical Press Ltd, Antiviral Therapy, Antiviral Therapy, International Medical Press, 2009, 14 (8), pp.1065-74. ⟨10.3851/IMP1462⟩, Antiviral Therapy, 2009, 14 (8), pp.1065-74. ⟨10.3851/IMP1462⟩, Antiviral therapy (Lond.) 14 (2009): 1065–1074. doi:10.3851/IMP1462, info:cnr-pdr/source/autori:Bohlius, Julia; Schmidlin, Kurt; Costagliola, Dominique; Faetkenheuer, Gerd; May, Margaret; Maria Caro-Murillo, Ana; Mocroft, Amanda; Bonnet, Fabrice; Clifford, Gary; Karafoulidou, Anastasia; Miro, Jose M.; Lundgren, Jens; Chene, Genevieve; Egger, Matthias/titolo:Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study/doi:10.3851%2FIMP1462/rivista:Antiviral therapy (Lond.)/anno:2009/pagina_da:1065/pagina_a:1074/intervallo_pagine:1065–1074/volume:14
- Publication Year :
- 2009
-
Abstract
- Background Incidence and risk factors of HIV-associated non-Hodgkin's lymphoma (NHL) are not well defined in the era of combination antiretroviral therapy (cART). Methods A total of 56,305 adult HIV type-1 (HIV-1)-infected patients who started cART in 1 of 22 prospective studies in Europe were included. Weibull random effects models were used to estimate hazard ratios (HRs) for developing systemic NHL and included CD4+ T-cell counts and viral load as time-updated variables. Results During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain lymphoma (PBL). The incidence rate of systemic NHL was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 (95% confidence interval [CI] 0.37–0.53). The corresponding incidence rates of PBL were 57 and 24 per 100,000 person-years (rate ratio 0.43, 95% CI 0.25-0.73). Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing ≤500 with 10,000-99,999 copies/ml) and increases in CD4+ T-cell counts (HR 0.30, 0.22-0.42, comparing ≥350 with 100-199 cells/pl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of AIDS), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing ≥50 with 16-29 years) were risk factors for systemic NHL. Conclusions The incidence rates of both systemic NHL and PBL were substantially reduced in patients on cART. Timely initiation of therapy is key to the prevention of NHL in the era of cART.
- Subjects :
- Male
HIV Infections
Rate ratio
0302 clinical medicine
cohort studies
Risk Factors
immune system diseases
hemic and lymphatic diseases
HIV Infection
Pharmacology (medical)
030212 general & internal medicine
Prospective cohort study
Lymphoma, AIDS-Related
Brain Neoplasms
non-Hodgkin lymphoma
Incidence
Lymphoma, Non-Hodgkin
Medicine (all)
Incidence (epidemiology)
Hazard ratio
Non-Hodgkin's Lymphoma
virus diseases
viral load
3. Good health
Europe
Infectious Diseases
030220 oncology & carcinogenesis
multicohort study
Drug Therapy, Combination
Female
Viral load
Human
Adult
Cart
HIV patients
medicine.medical_specialty
Anti-HIV Agents
antiretroviral therapy
Article
AIDS-related lymphoma
Brain Neoplasm
03 medical and health sciences
Internal medicine
mental disorders
medicine
Humans
Pharmacology
business.industry
Risk Factor
Kaposi sarcoma
Anti-HIV Agent
medicine.disease
Non-Hodgkin's lymphoma
nervous system
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Immunology
HIV-1
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Cohort Studie
business
immunodeficiency
Subjects
Details
- Language :
- English
- ISSN :
- 13596535
- Database :
- OpenAIRE
- Journal :
- Antiviral therapy, 14(8), 1065-1074. International Medical Press Ltd, Antiviral Therapy, Antiviral Therapy, International Medical Press, 2009, 14 (8), pp.1065-74. ⟨10.3851/IMP1462⟩, Antiviral Therapy, 2009, 14 (8), pp.1065-74. ⟨10.3851/IMP1462⟩, Antiviral therapy (Lond.) 14 (2009): 1065–1074. doi:10.3851/IMP1462, info:cnr-pdr/source/autori:Bohlius, Julia; Schmidlin, Kurt; Costagliola, Dominique; Faetkenheuer, Gerd; May, Margaret; Maria Caro-Murillo, Ana; Mocroft, Amanda; Bonnet, Fabrice; Clifford, Gary; Karafoulidou, Anastasia; Miro, Jose M.; Lundgren, Jens; Chene, Genevieve; Egger, Matthias/titolo:Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study/doi:10.3851%2FIMP1462/rivista:Antiviral therapy (Lond.)/anno:2009/pagina_da:1065/pagina_a:1074/intervallo_pagine:1065–1074/volume:14
- Accession number :
- edsair.doi.dedup.....d3eface2df0f706e0031b2b0d7ffdef0